Stockreport

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]

Xilio Therapeutics, Inc.  (XLO) 
PDF with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and commercialize XTX301, a tumor-activ [Read more]